Valuation: Compass Therapeutics, Inc.

Market Cap 344M 299M 278M 256M 483M 32.84B 490M 3.28B 1.29B 16.35B 1.29B 1.26B 54.81B P/E 2026 *
-4.38x
P/E 2027 * -4.11x
Enterprise Value 194M 169M 157M 144M 272M 18.52B 276M 1.85B 726M 9.22B 728M 712M 30.91B EV / Sales 2026 *
-94.3x
EV / Sales 2027 * 8.39x
Free-Float
87.55%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 65 2024-05-27
Director of Finance/CFO 54 2024-12-08
Chief Tech/Sci/R&D Officer 50 2025-12-31
Director TitleAgeSince
Director/Board Member 65 2013-12-31
Director/Board Member 64 2014-12-31
Chairman 61 2014-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-10.80%+32.67% - - 344M
+2.35%+2.74%+38.10%+71.29% 56.54B
-0.21%-7.38%+27.52%+61.15% 53.6B
-2.44%+1.40%-15.61%-15.45% 22.91B
-2.85%-7.78%-9.28%+345.55% 21.37B
+2.49%-0.92%+23.57%-13.14% 20.27B
+0.79%-1.06%+33.99%-31.95% 17.56B
+0.58%-5.88%+19.40%+527.50% 14.75B
+3.41%-6.61%+162.81%+278.22% 13.53B
-5.25%-4.23%+42.32%+170.15% 13.33B
Average -1.19%-3.79%+35.87%+154.81% 25.98B
Weighted average by Cap. +0.21%-2.96%+30.79%+116.84%

Financials

2026 *2027 *
Net sales -2.06M -1.79M -1.66M -1.53M -2.89M -196M -2.93M -19.62M -7.7M -97.76M -7.73M -7.56M -328M 25.27M 21.97M 20.45M 18.77M 35.45M 2.41B 36M 241M 94.59M 1.2B 94.9M 92.82M 4.03B
Net income -82.44M -71.66M -66.7M -61.24M -116M -7.87B -117M -786M -309M -3.92B -310M -303M -13.14B -89.57M -77.86M -72.47M -66.54M -126M -8.55B -128M -854M -335M -4.26B -336M -329M -14.27B
Net Debt -150M -130M -121M -111M -210M -14.32B -214M -1.43B -561M -7.13B -563M -551M -23.9B -132M -115M -107M -98.06M -185M -12.6B -188M -1.26B -494M -6.27B -496M -485M -21.04B
Logo Compass Therapeutics, Inc.
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
1.910USD
Average target price
8.500USD
Spread / Average Target
+345.03%

Quarterly revenue - Rate of surprise